Compare AGYS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGYS | MLYS |
|---|---|---|
| Founded | 1963 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 1994 | 2023 |
| Metric | AGYS | MLYS |
|---|---|---|
| Price | $102.58 | $26.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $111.67 | $48.67 |
| AVG Volume (30 Days) | 338.6K | ★ 2.0M |
| Earning Date | 05-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 67.07 | 37.43 |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $319,312,000.00 | N/A |
| Revenue This Year | $17.65 | N/A |
| Revenue Next Year | $14.36 | N/A |
| P/E Ratio | $71.18 | ★ N/A |
| Revenue Growth | ★ 15.85 | N/A |
| 52 Week Low | $61.50 | $12.59 |
| 52 Week High | $144.82 | $47.65 |
| Indicator | AGYS | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 73.50 | 49.44 |
| Support Level | $98.00 | $25.40 |
| Resistance Level | $130.58 | $30.85 |
| Average True Range (ATR) | 4.57 | 1.20 |
| MACD | 0.39 | 0.28 |
| Stochastic Oscillator | 86.84 | 81.48 |
Agilysys Inc provides hospitality software delivering cloud-native SaaS and on-premise solutions for hotels, resorts, cruise lines, casinos, corporate foodservice management, restaurants, universities, stadiums, and healthcare facilities. The company's software solutions include point-of-sale (POS), property management (PMS), inventory and procurement, payments, and related applications that manage and enhance the entire guest journey. It derives maximum revenue from the provision of software subscription and maintenance services, followed by the provision of professional services, and the sale of products (proprietary software licenses, third-party hardware, and operating systems). Agilysys operates across North America, Europe, the Middle East, Asia-Pacific, and India.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.